A study of ABO-202 for patients with infantile neuronal ceroid lipofuscinosis.
Phase of Trial: Phase I
Latest Information Update: 06 Oct 2016
At a glance
- Drugs ABO 202 (Primary)
- Indications Neuronal ceroid lipofuscinosis
- Focus Adverse reactions
- 06 Oct 2016 New trial record
- 21 Sep 2016 According an Abeona Therapeutics media release, this trial anticipates to initiate in 2017.